| Literature DB >> 35055294 |
Miral Al Sharabati1,2, Rana Sabouni1,2, Ghaleb A Husseini1,2.
Abstract
Metal-organic frameworks (MOFs) are a novel class of porous hybrid organic-inorganic materials that have attracted increasing attention over the past decade. MOFs can be used in chemical engineering, materials science, and chemistry applications. Recently, these structures have been thoroughly studied as promising platforms for biomedical applications. Due to their unique physical and chemical properties, they are regarded as promising candidates for disease diagnosis and drug delivery. Their well-defined structure, high porosity, tunable frameworks, wide range of pore shapes, ultrahigh surface area, relatively low toxicity, and easy chemical functionalization have made them the focus of extensive research. This review highlights the up-to-date progress of MOFs as potential platforms for disease diagnosis and drug delivery for a wide range of diseases such as cancer, diabetes, neurological disorders, and ocular diseases. A brief description of the synthesis methods of MOFs is first presented. Various examples of MOF-based sensors and DDSs are introduced for the different diseases. Finally, the challenges and perspectives are discussed to provide context for the future development of MOFs as efficient platforms for disease diagnosis and drug delivery systems.Entities:
Keywords: disease diagnosis; drug delivery; metal−organic frameworks; theranostic agent
Year: 2022 PMID: 35055294 PMCID: PMC8780624 DOI: 10.3390/nano12020277
Source DB: PubMed Journal: Nanomaterials (Basel) ISSN: 2079-4991 Impact factor: 5.076
Figure 1Nanotechnology applications in the biomedical field.
Nanocarriers for targeted drug delivery.
| Nanocarriers | Structures | Advantages | Disadvantages | References |
|---|---|---|---|---|
| Liposomes |
| Biocompatibility, | Instability, low encapsulation efficiency, insufficient drug loading, poor controlled drug release, shorter circulation times in the blood, poor storage stability, weak chemical and physical protection of sensitive drugs | [ |
| Polymeric Micelles (PMs) |
| Biostability, high drug loading capacity, easy to functionalize their surface, long circulation times in blood, reduction in side effects, targeted and controlled drug release | Immature drug release, prone to aggregation and opsonization in the bloodstream | [ |
| Carbon Nanotubes (CNTs) (inorganic) |
| Dynamic strength, unique physiochemical properties, high drug entanglement, intrinsic stability, good biocompatibility, structural flexibility, suitable surface functionalization, low cytotoxicity | Potential asbestos-like effects, low drug delivery capacity within the CNTs | [ |
| Quantum Dots (QDs) (inorganic) |
| Distinctive electronic properties, luminescence | Derivatization and ligands required | [ |
Figure 2(a) The number of synthesized MOFs per year reported in the Cambridge Structural Database (CSD). (b) The number of publications per year having the keyword “Metal−organic framework(s)”, retrieved from the Web of Science on 11 July 2021.
Figure 3Examples of typical metal−organic frameworks [66].
Figure 4MOF synthesis methods.
Figure 5Mechanochemical synthesis of MOFs.
Figure 6Solvothermal synthesis of MOFs.
Figure 7Biomedical applications of MOFs.
Figure 8(a) The number of publications featuring the terms “metal−organic framework” and “bioimaging,” “biosensing,” “biocatalysis”, and “drug delivery” in their topic. Retrieved from the Web of Science on 11 July 2021. (b) Major milestones in the biomedical applications of MOFs [126].
Biomedical applications of MOFs with examples.
| Biomedical Application | Technique | Description | Reference |
|---|---|---|---|
| Drug Delivery | Encapsulation of therapeutic cargoes | Includes: The two-step encapsulation route, where the size of molecules are < than MOFs pores. In-situ encapsulation routes, where the size of molecules are > than MOFs pores such as proteins | [ |
| Conjugations of therapeutic agents to the linkers | The attachment of therapeutic agents to ligands via orthogonal conjugation. An example would be the incorporation of amino groups into the framework by doping the terephthalic acid ligand with 2-aminoterephthalic acid during the growth of Fe-MIL-101 MOFs. | [ | |
| Therapeutic agents as linkers | Direct incorporation of therapeutics as building blocks for MOF synthesis such as the synthesis of MOFs with porphyrin derivative-based linkers for photodynamic therapy (PDT). An example would be the synthesis of Hf–porphyrin nanoscale DBP–UiO MOF. | [ | |
| Bioimaging | Magnetic Resonance Imaging (MRI) | A diagnostic method dependent on the nuclear magnetic resonance of particles in the body that produces computerized images by analyzing the absorption and transmission of high-frequency radio waves. Mn, Fe, and Gd-based MOFs are some examples of potential candidates for this application. | [ |
| X-ray Computed Tomography Imaging (CT) | A 3-D visualization of internal structures based on the mitigation of X-rays that produces a sequence of tomographic images at various orientations. Photoactive (UiO-PDT) MOF is an example of a CT contrast agent | [ | |
| Optical Imaging (OI) | Light illumination is used to achieve real-time visualization with minimally invasive operations. An example is the incorporation of indocyanine green (ICG) into MIL-100(Fe) with a high loading capacity of 40 wt%, which is coated with a layer of hyaluronic acid (HA) for tumor-targeting. | [ | |
| Positron Emission Tomography (PET) | High-resolution 3D images of metabolic processes in the body are given by recording the positrons emission from radioactive materials piling up at the target organs or tissues. Zr-based MOFs were used for PET imaging. | [ | |
| Biosensing | Nucleic acid sensing | Nucleic acid levels facilitate disease diagnosis and observe biological systems since DNAs and RNAs are crucial for physiological control. The incorporation of the triplex-forming oligonucleotide with H2dtoaCu MOFs to detect HIV DNA sequences is one example of this method. | [ |
| Intracellular molecules sensing | Many diseases can be reflected by the presence of small biomolecules such as glucose and metal ions in the tissue. R-UiO based bio-MOF was used as a phosphorescence/fluorescence dual-emissive platform for intracellular oxygen ratio measurement. | [ | |
| Intracellular pH sensing | The reflection of the alternations of physiological environments. | [ | |
| Intracellular temperature sensing | The detection of the temperature difference between normal and diseased cells. Thermosensitive near-infrared LnMOF is an example. | [ | |
| Biocatalysis | Biomimetic catalysis | Certain MOFs have very effective catalysis as well as very low toxicity features. This makes them appropriate candidates for disease diagnosis and immunoassay. Nanometric MIL-100 implemented the intrinsic peroxidase-like catalytic activity for ascorbic acid colorimetric sensing. | [ |
Types of stimuli used in drug delivery.
| Type of Triggers | Examples | Examples of MOFs | Drugs and applications | Remarks | Reference |
|---|---|---|---|---|---|
| Internal | pH | Hollow mesoporous silica at a zeolitic imidazolate framework (HMS@ZIF) | Doxorubicin (DOX), anticancer therapy | Engineer a system that can utilize the pH differences between the blood and the diseased cells to enable drug delivery to chosen sites. | [ |
| MIL-100(Fe) | Camptothecin (CPT), anticancer therapy | ||||
| ZIF-8 | D-α-Tocopherol succinate (α-TOS), antitumor therapy | ||||
| Temperature | Zinc MOF constructed by semirigid 5-(4′-carboxyphenoxy) nicotinic acid (Zn-cpon-1) | 5-fluorouracil (5-FU), anticancer therapy | Design a delivery system that will merely release the drug at temperatures beyond 37 °C. | [ | |
| Zinc glycolate MOF (Zn-GA) | Methotrexate (MTX), anticancer treatment | ||||
| UiO-66 | 5-Fu, chemophotothermal therapy | ||||
| Redox potential (Glutathione (GSH) concentration) | Zinc-based 4,4′-dithiobisbenzoic acid MOF (MOF-Zr (DTBA)) | Curcumin (CCM), anticancer therapy | Exploit the concentration gradient between normal and diseased cells, and between intracellular and extracellular environments for targeted drug delivery to certain sites. | [ | |
| Cyclodextrin MOFs (CD-MOFs) | DOX, anticancer therapy | ||||
| Zr-MOF | Cisplatin, anticancer therapy | ||||
| Enzyme concentration | Porphyrinic MOF (PCN-224) | DOX, anticancer therapy | Design a system by incorporating a certain peptide sequence or chemical bond that is prone to be attacked by disease-related enzymes. | [ | |
| UiO-68 | CPT, anticancer therapy | ||||
| External | Ultrasound | NH2-Fe-BDC | DOX, anticancer therapy | Apply local sonication after the injection of encapsulated drugs for targeted delivery purposes. This enables the uniform distribution of micelles and the drug across the pathological cell. | [ |
| Fe-NDC | Calcein and DOX, anticancer therapy | ||||
| Magnetic Field | HKUST-1 | Nimesulide, anticancer treatment | After administration, the drug immobilized magnetite carrier can pile up at the targeted site under the course of an external magnetic field. | [ | |
| PD/M-NMOF | DOX & MB, anticancer treatment | ||||
| ZIF-8@ABFs | RhB | ||||
| Light | o-NBA@ZIF-8 | rifampicin (RFP), bacterial infection therapy | Design a light-sensitive system that goes through reverse disruption under the action of light to enable external control of drug release. | [ | |
| UiO-AZB | 5-FU, anticancer therapy | ||||
| AuNR@MOFs | CPT, anticancer therapy | ||||
| Heat | CP5-capped UiO-66-NH-Q | 5-FU, treatment of central nervous system diseases | Apply an external heat source to raise the temperature of the cellular environment. | [ | |
| CP5-capped UiO-66-NH-A | 5-FU, anticancer therapy |
Classification of neurological diseases [201].
| Neurological Disorders | Examples |
|---|---|
| Neurotraumatic diseases | Stroke, spinal cord injury, and traumatic brain injury |
| Neurodegenerative diseases | Alzheimer’s, Parkinsons, and Huntingtons |
| Neuropsychiatric diseases | Autism, depression, and hyperactivity |
MOFs used for the detection of metal ions related to Alzheimer’s disease.
| Metal Ion | MOF | Remarks | Reference |
|---|---|---|---|
| Zn2+ | Cd2(L1)(DMF)2(H2O)2 | Zinc ions were selectively fluorescent detected over mixed metal ions in a methanol solution. | [ |
| Cu2+ | [Me2NH2][Eu(ox)2(H2O)]·3H2O | A 3D Eu-MOF was decomposed upon the exchange of copper ions with a cationic guest molecule, leading to luminescent quenching. | [ |
| Al3+ | Eu(L4)(OAc)(DMA) | The attachment of aluminum ions on the probe’s surface reduces the energy transfer between Eu3+ and the ligand, resulting in luminescent quenching. | [ |
| Fe3+ | BUT-14 | BUT-15 showed a better sensing ability as its pyridine N donors donate their long-pair electrons to Fe3+ ions. | [ |
Ocular diseases with their MOF-based DDSs.
| Ocular Disease | Description | MOF Nanocarrier | Drug | Loading Capacity | Remarks | Reference |
|---|---|---|---|---|---|---|
| Glaucoma |
It affects the anterior segment of the eye and is characterized by an increased pressure in the eyes that damages the optical nerve. It is the second leading cause of irreversible blindness worldwide. Known as “the silent thief of sight” as it has no symptoms or signs | UiO-67 | Brimonidine | 50–60 wt% | Cytotoxicity assays showed the high biocompatibility of the MOFs. | [ |
| NH2-MIL-88(Fe) | 121.3 μg mg−1 | In vivo studies showed that the nanocarriers stayed on the preocular surface for a long period (4 h), resulting in an increase in drug bioavailability. | [ | |||
| Zr-based UiO-67 and polyurethane MOF (UiO-67@ PU) | 58.4 mg g−1 | The MOF-based polymer nanocomposite showed a prolonged drug release (14 days). | [ | |||
| Photoreceptor Degeneration |
It is one of the most refractory oculopathy in the world. Severe cases suffer from vision loss. | Nanoscale zirconium-porphyrin MOF (NPMOF) | Methylprednisolone (MPS) | 97.3 wt% | NPMOF demonstrated excellent in vivo biocompatibility and low biotoxicity. | [ |
Examples of MOF therapeutic platforms for antibacterial applications.
| MOF Platform | Bacteria | Drug | Remarks | Reference |
|---|---|---|---|---|
| Fe-MIL-101-NH2 |
| Isoniazid | A theranostic agent for drug delivery and imaging properties. | [ |
| MIL-100 (Fe) nanoparticles (NPs) |
| 3-azido-d-alanine (D-AzAla) | Fast degradation and accumulation after intravenous injection. | [ |
| MOF-53 (Fe) nanoparticles (NPs) |
| vancomycin (Van) | Efficient drug loading capacity of 20 wt% and high antibacterial efficiency of 99.3%. | [ |
| Fe3O4@PAA@ZIF-8 |
| ciprofloxacin (CIP) | High loading capacity (93%) and drug release (73%). | [ |
| Ag-doped magnetic microporous γ-Fe2O3@SiO2@ZIF-8-Ag (FSZ-Ag) |
| - | Release of 80% of Ag in the solutions, leading to the suppression of bacteria growth. | [ |
| hydrogel@ Cu-MOF |
| - | Excellent antibacterial activity at 2 mg mL−1 due to the large surface area to volume ratio and the antibacterial property of copper. | [ |
| Ag-doped carbonized ZIF nanocomposites(C-Zn/Ag) |
| - | Fast and safe wound sterilization and can be an alternative to antibiotics. | [ |
| L-arginine and glucose oxidase encapsulated Cu-MOFs (L-Arg/GO |
| - | Coencapsulation of glucose oxidase (GO | [ |
| Silver-based metal−organic framework embellished with graphene-oxide (GO-Ag-MOF) |
| - | Outstanding antibacterial activity | [ |
MOFs used as therapeutic agents for other types of diseases.
| Disease | Description | MOF platform | Remarks | Reference |
|---|---|---|---|---|
| Chronic kidney disease (CKD) | It is defined by the gradual loss of kidney function over time. | DIBc NMOF | Significant improvement and recovery of | [ |
| Chronic Toxoplasmosis | It is caused by infection with the Toxoplasma gondii parasite | Curcumin@Fe-MOF and UiO-66-NH2 | Treatment of infected rats with these nanocomposites resulted in a significant decrease in the number of brain cysts (parasite load). | [ |
| Hemorrhagic Shock | It occurs due to large amounts of blood loss which leads to reduced cardiac output and tissue perfusion | ZIF-8 encapsulating free hemoglobin (ZIF-8@Hb) | Better biocompatibility, less protein adsorption, and macrophage uptake. | [ |